VRTX Stock Recent News

Following a challenge brought by Vertex Pharmaceuticals Incorporated, BBB National Programs' National Advertising Division will refer claims made by Maze Therapeutics, Inc. to the appropriate regulatory authorities for review and possible enforcement action for failure to submit a substantive response to the National Advertising Division's (NAD) inquiry. Following a challenge brought by Vertex Pharmaceuticals Incorporated, BBB National Programs' National Advertising Division will refer claims made by Maze Therapeutics, Inc. to the appropriate regulatory authorities for review and possible enforcement action for failure to submit a substantive response to the National Advertising Division's (NAD) inquiry.

Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Live Updates Live Coverage Has Ended Goldman Sachs just reiterated its buy rating on Nvidia 8:55 am Just this morning, analysts at Goldman Sachs reiterated a buy rating on Nvidia, ahead of earnings. “To be clear, we remain very bullish on Nvidia’s prospects for driving outsized growth in 2026, based on positive hyperscaler CapEx commentary and the prospects for non-traditional customer demand we see,” as quoted by CNBC. Bank of America reiterated its buy rating on Apple, citing a potential iPhone event. “Some media reports and tech websites are highlighting Tues Sep 9th, as a potential launch date for iPhone 17 (not official yet), with pre-orders starting Friday, Sep 12th, and new iPhones reaching stores on Fri Sep 19th,” as also quoted by CNBC. At the moment, futures are pointing to a lower open. The Dow Jones is down about 105 points. The S&P 500 is down 19, with the Nasdaq down about 87 points. There are hopes that markets can continue to rally. Especially after Federa

Vertex Pharmaceuticals (VRTX -0.45%) is usually a market-beater, but it hasn't been so over the past year. The company's shares are down 18% over the trailing-12-month period due to a combination of headwinds.

What goes up can come down. Most investors have experienced this first-hand with stocks in their portfolio.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Susie Lisa, Senior Vice President, Investor Relations, and Manisha Pai, Executive Director, Investor Relations, will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, at 11:00 a.m. ET. Reshma Kewalramani, President and Chief Executive Officer, and Duncan McKechnie, Executive Vice P.

Vertex Pharmaceuticals (VRTX 0.17%) has been a top pharma stock in recent years. It has been generating strong revenue growth while also building out its portfolio of drugs, expanding its growth opportunities in the process.

This week's Undercovered Dozen spotlights 12 lesser-known stocks and ETFs, offering unique investment opportunities across gold, biotech, income, and tech sectors. B2Gold and Vertex Pharmaceuticals stand out as strong buys, driven by robust fundamentals, sector leadership, and clear growth catalysts for 2025 and beyond. Caution is urged on popular income-focused ETFs like SPYI and ULTY, as structural flaws and capped upside may limit long-term wealth compounding.

We're well into the home stretch of 2025. August is more than halfway over.

Even well-established drugmakers can lose significant market value overnight following a setback. That's what recently happened to Vertex Pharmaceuticals (VRTX 0.47%).